Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine
Cephalalgia · 2025
DOI: 10.1177/03331024251368757 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cephalalgia, 2025. Verfasst von Michael P Johnson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Eli Lilly and Company, Indianapolis, IN, USA. Hauptthemen laut MEDLINE: Migraine Disorders, Pituitary Adenylate Cyclase-Activating Polypeptide, Antibodies, Monoclonal, Antibodies, Neutralizing. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: This study is sponsored by Eli Lilly and Company..
Abstract (Originalsprache)
Aim
LY3451838 is a monoclonal antibody against pituitary adenylate cyclase-activating peptide (PACAP), a target in migraine research. The present study aimed to evaluate LY3451838 as a preventive treatment for participants with treatment-resistant migraine.
Methods
Following preclinical assessment of LY3451838, including pharmacokinetic and pharmacodynamic studies, safety was evaluated in a phase 1 study of LY3451838 (n = 33) versus placebo (n = 13) in healthy participants. A phase 2 trial was carried out in treatment-resistant participants with chronic migraine (CM) (n = 16) or episodic migraine (EM) (n = 22). In phase 2, participants received a single intravenous (IV) dose of 1500 mg LY3451838 (n = 19) or placebo (n = 19) and completed ePRO daily diaries. Participants were followed for safety for 140 days.
Results
In phase 2, at one-month post-dose, patients who had received a single IV dose of LY3451838 exhibited greater changes from baseline than placebo in mean monthly migraine headache days in both the CM and EM subgroups (CM: −4.7 days vs. −3.0 days; EM: −1.7 days vs. −1.2 days), but the treatment contrast was not statistically significant in either subgroup. Similar non-significant results were seen at the three-month time point. The percentage of participants reporting treatment-emergent adverse events was similar for LY3451838 and placebo, with one serious adverse event of B-cell lymphoma in an LY3451838-treated participant that led to study discontinuation.
Conclusions
LY3451838 did not demonstrate superior efficacy over placebo in patients with treatment-resistant CM or EM. However, the difference observed between LY3451838 and placebo among CM patients is similar to the statistically significant difference reported in the recent HOPE trial, which primarily consisted of CM patients. Further clinical research with larger sample sizes is needed to inform on the utility of blocking PACAP in various migraine populations. Trial Registration ClinicalTrials.gov: NCT03692949 (phase 1); NCT04498910 (phase 2).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Eli Lilly and Company, Indianapolis, IN, USA.
- EMB Statistical Solutions, LLC, Overland Park, KS, USA.
- Bio Behavioral Health, Toms River, NJ, USA.
ORCID-Profile: Michael P Johnson
Förderung
- This study is sponsored by Eli Lilly and Company.
Zitieren
APA
Johnson, M. P., Krikke-Workel, J., Patel, C. N., Morin, S. M., Turner, P. K., Clark, K. A., Donley, D., Jin, Y., Johnson, K. W., Vincent, M., Stille, J. R., Broad, L. M., & Patel, A. (2025). Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine. Cephalalgia. https://doi.org/10.1177/03331024251368757
Vancouver
Johnson MP, Krikke-Workel J, Patel CN, Morin SM, Turner PK, Clark KA, et al. Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine. Cephalalgia. 2025. doi:10.1177/03331024251368757
BibTeX
@article{Johnson2025,
author = {Johnson, Michael P and Krikke-Workel, Judith and Patel, Chetan N and Morin, S Michelle and Turner, P Kellie and Clark, Kristie A and Donley, David and Jin, Yan and Johnson, Kirk W and Vincent, Maurice and Stille, John R and Broad, Lisa M and Patel, Ashok},
title = {Preclinical and clinical evaluation of LY3451838, a PACAP-neutralizing monoclonal antibody, in randomized, double-blind, placebo-controlled phase 1 and phase 2 studies involving healthy adults and adults with treatment-resistant migraine},
journal = {Cephalalgia},
year = {2025},
doi = {10.1177/03331024251368757}
}
EUVIMED